Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Alterity Therapeutics Limited (ATH.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.01300.0000 (0.00%)
At close: 03:51PM AEDT
Advertisement

Alterity Therapeutics Limited

460 Bourke Street
Level 3
Melbourne, VIC 3000
Australia
61 3 9349 4906
https://alteritytherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. Geoffrey Paul Kempler B.Sc, B.Sc.Co-Founder & Non-Exec. Chairman387.8kN/A1955
Dr. David A. Stamler M.D.Chief Exec. Officer658.39kN/A1961
Ms. Kathryn J. E. AndrewsChief Financial Officer327.26kN/A1967
Dr. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of R&D Advisory BoardN/AN/A1959
Dr. Steven D. TargumChief Medical AdvisorN/AN/AN/A
Dr. Robert ChernyHead of ResearchN/AN/AN/A
Mr. Phillip Allen Hains BBus(Acc), CA, MBACompany Sec.N/AN/A1959
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Corporate Governance

Alterity Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement